Evaluation of the effectiveness and safety of Sofosbuvir plus Daclatasvir in the treatment for HCV or HIV/HCV with hemophilia
Not Applicable
Recruiting
- Conditions
- Hepatitis C with hemophilia patient
- Registration Number
- JPRN-UMIN000021544
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
HCV-genotype is only GT1 or GT2. Subjects with un-compensate cirrhosis Serious renal dysfunction (eGFR<30ml/min/1.73m2) Positive of HBs antigen QTcF 500>msec or second/thrid degree of AV-block in ECG Have active oppotunistic infection required treatment. The following concomitant medications are not permitted : Rifampicin, Rifabutin, Phenytoin, Carbamazepine, Phenobarbital, Dexamethasone (given whole body), St. John's wort. In the opinion of the Investigator makes the subject unsuitable for enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method